KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Total Non-Current Liabilities (2016 - 2026)

NovoCure's Total Non-Current Liabilities history spans 13 years, with the latest figure at $239.6 million for Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities rose 66.94% to $239.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $239.6 million, a 66.94% increase, with the full-year FY2025 number at $240.6 million, up 93.73% from a year prior.
  • Total Non-Current Liabilities hit $239.6 million in Q1 2026 for NovoCure, roughly flat from $240.6 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for NVCR hit a ceiling of $681.2 million in Q2 2024 and a floor of $124.2 million in Q4 2024.
  • Historically, Total Non-Current Liabilities has averaged $428.6 million across 5 years, with a median of $586.5 million in 2022.
  • Biggest five-year swings in Total Non-Current Liabilities: tumbled 79.45% in 2024 and later skyrocketed 93.73% in 2025.
  • Tracing NVCR's Total Non-Current Liabilities over 5 years: stood at $591.7 million in 2022, then grew by 2.17% to $604.5 million in 2023, then tumbled by 79.45% to $124.2 million in 2024, then soared by 93.73% to $240.6 million in 2025, then fell by 0.42% to $239.6 million in 2026.
  • Business Quant data shows Total Non-Current Liabilities for NVCR at $239.6 million in Q1 2026, $240.6 million in Q4 2025, and $243.9 million in Q3 2025.